Literature DB >> 20307591

Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies.

Andrea Jegerlehner1, Melanie Wiesel, Klaus Dietmeier, Franziska Zabel, Dominique Gatto, Philippe Saudan, Martin F Bachmann.   

Abstract

Pre-existing immunity against vaccine carrier proteins has been reported to inhibit the immune response against antigens conjugated to the same carrier by a process termed carrier induced epitopic suppression (CIES). Hence understanding the phenomenon of CIES is of major importance for the development of conjugate vaccines. Virus-like particles (VLPs) are a novel class of potent immunological carriers which have been successfully used to enhance the antibody response to virtually any conjugated antigen. In the present study we investigated the impact of a pre-existing VLP-specific immune response on the development of antibody responses against a conjugated model peptide after primary, secondary and tertiary immunization. Although VLP-specific immune responses led to reduced peptide-specific antibody titers, we showed that CIES against peptide-VLP conjugates could be overcome by high coupling densities, repeated injections and/or higher doses of conjugate vaccine. Furthermore we dissected VLP-specific immunity by adoptively transferring VLP-specific antibodies, B-cells or T(helper) cells separately into naïve mice and found that the observed CIES against peptide-VLP conjugates was mainly mediated by carrier-specific antibodies. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20307591     DOI: 10.1016/j.vaccine.2010.02.103

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  39 in total

1.  PhiXing-it, displaying foreign peptides on bacteriophage ΦX174.

Authors:  Kristofer J Christakos; Janice A Chapman; Bentley A Fane; Samuel K Campos
Journal:  Virology       Date:  2015-12-03       Impact factor: 3.616

2.  A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory.

Authors:  Hayk Davtyan; Anahit Ghochikyan; Armine Hovakimyan; Arpine Davtyan; Richard Cadagan; Annette M Marleau; Randy A Albrecht; Adolfo García-Sastre; Michael G Agadjanyan
Journal:  J Neuroimmunol       Date:  2014-10-16       Impact factor: 3.478

3.  Optimization of a multivalent peptide vaccine for nicotine addiction.

Authors:  David F Zeigler; Richard Roque; Christopher H Clegg
Journal:  Vaccine       Date:  2019-02-13       Impact factor: 3.641

Review 4.  Plant-derived virus-like particles as vaccines.

Authors:  Qiang Chen; Huafang Lai
Journal:  Hum Vaccin Immunother       Date:  2012-09-20       Impact factor: 3.452

5.  Titrating T-cell epitopes within self-assembled vaccines optimizes CD4+ helper T cell and antibody outputs.

Authors:  Rebecca R Pompano; Jianjun Chen; Emily A Verbus; Huifang Han; Arthur Fridman; Tessie McNeely; Joel H Collier; Anita S Chong
Journal:  Adv Healthc Mater       Date:  2014-06-13       Impact factor: 9.933

6.  The entirely carbohydrate immunogen Tn-PS A1 induces a cancer cell selective immune response and cytokine IL-17.

Authors:  Ravindra A De Silva; Dananjaya K Appulage; Halina Pietraszkiewicz; Kevin R Bobbitt; Joe Media; JiaJiu Shaw; Fred A Valeriote; Peter R Andreana
Journal:  Cancer Immunol Immunother       Date:  2012-04       Impact factor: 6.968

7.  Dense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody responses to HIV-1 Env.

Authors:  Jonelle Mattiacio; Scott Walter; Matt Brewer; William Domm; Alan E Friedman; Stephen Dewhurst
Journal:  Vaccine       Date:  2011-02-18       Impact factor: 3.641

8.  Heterologous Prime-Boost Enhances the Antitumor Immune Response Elicited by Plant-Virus-Based Cancer Vaccine.

Authors:  Hui Cai; Sourabh Shukla; Chao Wang; Hema Masarapu; Nicole F Steinmetz
Journal:  J Am Chem Soc       Date:  2019-04-16       Impact factor: 15.419

9.  A bivalent antihypertensive vaccine targeting L-type calcium channels and angiotensin AT1 receptors.

Authors:  Hailang Wu; Yiyi Wang; Gongxin Wang; Zhihua Qiu; Xiajun Hu; Hongrong Zhang; Xiaole Yan; Fan Ke; Anruo Zou; Min Wang; Yuhua Liao; Xiao Chen
Journal:  Br J Pharmacol       Date:  2019-12-12       Impact factor: 8.739

10.  Cost-effective purification process development for chimeric hepatitis B core (HBc) virus-like particles assisted by molecular dynamic simulation.

Authors:  Bingyang Zhang; Shuang Yin; Yingli Wang; Zhiguo Su; Jingxiu Bi
Journal:  Eng Life Sci       Date:  2021-05-03       Impact factor: 2.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.